-+ 0.00%
-+ 0.00%
-+ 0.00%
Hong Kong stock changes|Pharmaceutical Juno-B (02126) rebounded more than 8%, the company clarified the cost dispute and expects to reduce the unit production cost of Nuoda by more than 65% starting next year
Share
Listen to the news

The Zhitong Finance App learned that Yao Ming Junuo B (02126) rebounded more than 8%. As of press release, it had risen 8.11% to HK$2.465, with a turnover of HK$3,018,900.

According to the news, on November 18, Pharmaceutical and Junuo's official account issued a clarification statement on recent online statements regarding the production cost and profit situation of Benodat®. The company stated that Benoda®'s medical insurance payment standard is RMB 288,600 and will be implemented from January 1, 2027. This payment standard is the result of the company comprehensively considering the clinical value of the product, patient accessibility, and sustainable enterprise management, and fully communicating with the national health insurance department.

With the promotion of independent supply of core raw materials such as lentivirus vectors, localized substitution of some raw materials and consumables, and continuous improvement in production efficiency, the company expects the unit production cost of Benoda® to drop by more than 65% from 2027 compared to the actual level in 2025. Furthermore, cost reduction has always been based on the premise of not lowering quality standards. Currently, the success rate of commercial production of Benodat® is over 99% at one time.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending